Cotinga Pharmaceuticals Inc. Stock price Toronto S.E.

Equities

COT

CA22675B2021

Biotechnology & Medical Research

Delayed Toronto S.E. 10:06:48 2020-10-14 am EDT 5-day change 1st Jan Change
0.035 CAD -41.67% Intraday chart for Cotinga Pharmaceuticals Inc. -22.22% -41.67%
Sales 2018 - Sales 2019 - Capitalization 1.61M 2.18M
Net income 2018 -4M -5.42M Net income 2019 -2M -2.71M EV / Sales 2018 -
Net cash position 2018 40.73K 55.14K Net cash position 2019 24.64K 33.36K EV / Sales 2019 -
P/E ratio 2018
-1.11 x
P/E ratio 2019
-0.6 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 69.18%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
President 46 14-12-31
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 61 17-06-11
Members of the board TitleAgeSince
Director/Board Member 63 18-06-30
Chairman - 07-02-19
President 46 14-12-31
More insiders
Cotinga Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. Its initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.
More about the company
  1. Stock
  2. Equities
  3. Stock Cotinga Pharmaceuticals Inc.
  4. Stock Cotinga Pharmaceuticals Inc. - Toronto S.E.